| Long-term safety ofin uteroexposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study M Chaparro, A Verreth, T Lobaton, E Gravito-Soares, M Julsgaard, ... Official journal of the American College of Gastroenterology| ACG 113 (3 …, 2018 | 182 | 2018 |
| Management of perianal fistulas in Crohn’s disease: an up-to-date review M Marzo, C Felice, D Pugliese, G Andrisani, G Mocci, A Armuzzi, L Guidi World Journal of Gastroenterology: WJG 21 (5), 1394, 2015 | 139 | 2015 |
| Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti‐TNF alpha: 5‐year follow‐up study D Pugliese, L Guidi, PM Ferraro, M Marzo, C Felice, L Celleno, R Landi, ... Alimentary pharmacology & therapeutics 42 (7), 880-888, 2015 | 112 | 2015 |
| Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants G Andrisani, D Frasca, M Romero, A Armuzzi, C Felice, M Marzo, ... Journal of Crohn's and Colitis 7 (4), 301-307, 2013 | 108 | 2013 |
| Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study A Armuzzi, C Felice, A Papa, M Marzo, D Pugliese, G Andrisani, ... Journal of Crohn's and Colitis 7 (12), e623-e629, 2013 | 106 | 2013 |
| Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future D Pugliese, C Felice, A Papa, A Gasbarrini, GL Rapaccini, L Guidi, ... Expert Review of Clinical Immunology 13 (3), 223-233, 2017 | 103 | 2017 |
| Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission A Armuzzi, D Pugliese, S Danese, G Rizzo, C Felice, M Marzo, ... Inflammatory bowel diseases 19 (5), 1065-1072, 2013 | 101 | 2013 |
| Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis A Armuzzi, D Pugliese, S Danese, G Rizzo, C Felice, M Marzo, ... Inflammatory bowel diseases 20 (8), 1368-1374, 2014 | 91 | 2014 |
| Adalimumab in active ulcerative colitis: a “real-life” observational study A Armuzzi, L Biancone, M Daperno, A Coli, D Pugliese, V Annese, ... Digestive and Liver Disease 45 (9), 738-743, 2013 | 89 | 2013 |
| Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents A Papa, C Felice, M Marzo, G Andrisani, A Armuzzi, M Covino, G Mocci, ... Journal of Crohn's and Colitis 7 (2), 113-119, 2013 | 89 | 2013 |
| Faecal calprotectin assay after induction with anti-tumour necrosis factor α agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year L Guidi, M Marzo, G Andrisani, C Felice, D Pugliese, G Mocci, O Nardone, ... Digestive and Liver Disease 46 (11), 974-979, 2014 | 88 | 2014 |
| Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience G Rizzo, A Armuzzi, D Pugliese, A Verbo, A Papa, C Mattana, ... International journal of colorectal disease 26, 1435-1444, 2011 | 86 | 2011 |
| Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: an … L Guidi, D Pugliese, TP Tonucci, A Berrino, B Tolusso, M Basile, ... Journal of Crohn's and Colitis 12 (9), 1079-1088, 2018 | 82 | 2018 |
| Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease—a multicenter retrospective European study U Kopylov, B Verstockt, L Biedermann, S Sebastian, D Pugliese, ... Inflammatory bowel diseases 24 (11), 2442-2451, 2018 | 74 | 2018 |
| Diet and nutrients in gastrointestinal chronic diseases A Corsello, D Pugliese, A Gasbarrini, A Armuzzi Nutrients 12 (9), 2693, 2020 | 55 | 2020 |
| The thrilling journey of SARS-CoV-2 into the intestine: from pathogenesis to future clinical implications F Scaldaferri, G Ianiro, G Privitera, LR Lopetuso, LM Vetrone, V Petito, ... Inflammatory Bowel Diseases 26 (9), 1306-1314, 2020 | 54 | 2020 |
| Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease G Privitera, S Onali, D Pugliese, S Renna, E Savarino, A Viola, ... Journal of Crohn's and Colitis 15 (2), 335-339, 2021 | 52 | 2021 |
| COVID-19 and intestinal inflammation: Role of fecal calprotectin V Ojetti, A Saviano, M Covino, N Acampora, E Troiani, F Franceschi, ... Digestive and Liver Disease 52 (11), 1231-1233, 2020 | 52 | 2020 |
| Assessment of neurological manifestations in hospitalized patients with COVID‐19 M Luigetti, R Iorio, AR Bentivoglio, L Tricoli, V Riso, J Marotta, C Piano, ... European journal of neurology 27 (11), 2322-2328, 2020 | 51 | 2020 |
| Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission F Palone, R Vitali, S Cucchiara, M Mennini, A Armuzzi, D Pugliese, ... Inflammatory bowel diseases 22 (12), 2886-2893, 2016 | 51 | 2016 |
